Drug General Information (ID: DDIHYLV5GT)
Drug Name			Glycerol phenylbutyrate		Drug Info		Deflazacort		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Urea Cycle Disorder Agents				Glucocorticoids
Structure

Mechanism of Glycerol phenylbutyrate-Deflazacort Interaction (Severity Level: Moderate)
Increased risk of hyperammonemia Click to Show/Hide Mechanism Graph
Drug Name		Glycerol phenylbutyrate				Deflazacort
Mechanism		Hyperammonemia				Hyperammonemia
Key Mechanism Factor 1
		Factor Name		Hyperammonemia
		Factor Description		Hyperammonemia is a metabolic disorder characterized by elevated levels of ammonia. The most common manifestations of hyperammonemia are neurological signs and symptoms that may be acute or chronic, depending on the underlying abnormality, and severe life-threatening complications such as cerebral edema and brain herniation can occur.
Mechanism Description		Increased risk of hyperammonemia by the combination of Glycerol phenylbutyrate and Deflazacort

Recommended Action
Management		Plasma ammonia levels should be closely monitored when corticosteroids, haloperidol, carbamazepine, topiramate, or phenobarbital are used in patients with urea cycle disorders receiving phenylbutyrate therapy.

References
1	Cerner Multum, Inc. "Australian Product Information.".
2	Product Information. Buphenyl (sodium phenylbutyrate). Horizon Pharma USA Inc, Northbrook, IL.
3	Product Information. Ravicti (glycerol phenylbutyrate). Hyperion Therapeutics Inc, South San Francisco, CA.